Blog

OncoSec Medical Promotes Veronica Vallejo to Chief Financial Officer

SAN DIEGO – February 19, 2013 — OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Vice President and Controller, Veronica Vallejo has been promoted to Chief Financial Officer effective February 8, 2013.

“Veronica has been an integral part of our team since the inception of OncoSec and this promotion is well deserved. Her strategic insights and strong financial acumen will be valuable to the future success and growth of the company,” said Punit Dhillon, President and CEO.

Veronica has over fifteen years of public accounting experience and has worked for nearly a decade in a senior management position. She has extensive experience in public company operations and all financing and accounting functions. Veronica holds a B.S. in Business Administration with an emphasis in accounting from San Diego State University.  She is a certified public accountant and a member of the American Institute of Certified Public Accountants.

 

 

 

The History and Future of Merkel Cell Carcinoma

California Sun

 

When researching and actively working towards the treatment of an emerging condition, it is important to pay close attention to the history of the disease and how it might help move forward the field of study and public awareness. Being a lesser-known form of cancer, Merkel cell carcinoma (MCC) has not been paid as close attention as its mortality rate should merit. At OncoSec, we believe that it is of high importance to advance the field of study surrounding MCC and to create a more effective treatment regimen.

Continue reading “The History and Future of Merkel Cell Carcinoma”

OncoSec Announces Issuance of New Patent for Method of Use

SAN DIEGO, CA — June 19, 2012 — OncoSec Medical Inc. (OTCBB:ONCS), a company developing the OncoSec Medical System (OMS) ElectroOncology therapies to treat advanced-stage solid tumors, announced the Commissioner of Patents, Commonwealth of Australia Patent Office recently granted a new Method of Use patent (Patent Application No. 2007224275, “Method and Device for Treating Microscopic Residual Tumors Remaining in Tissues Following Surgical Resection”) for the company’s OMS ElectroOncology treatment platform. The issuance of this patent has the potential to expand OncoSec’s market opportunities for minimally invasive and surgical procedures to treat solid tumors, as an adjunct therapy to earlier-stage cancers. Specifically, it allows OMS technology to be used to treat the margins of solid tumors following surgical resection.

One of the methods of treating solid tumors, which represent the majority of all cancer incidences, is surgical removal of the tumor along with removal of healthy tissue surrounding the main tumor mass. The purpose of removing this additional tissue is to ensure that peripheral cancerous cells are also eliminated in order to prevent recurrence. However, the removal of this healthy tissue may result in function loss and have potentially detrimental cosmetic effects. This jeopardizes a patient’s quality of life.

OMS ElectroChemotherapy is an investigational therapy being evaluated to reduce the rate of cancer recurrence without quality of life side effects. As a potential adjunct to surgery, this therapeutic approach involves removal (using a scalpel) of the tumor mass, without removal of excess healthy tissue, followed by treatment with OMS ElectroChemotherapy. This approach has been shown to selectively kill cancer cells that may exist in the surrounding tissue, which may result in a reduced rate of recurrence and the potential to complement standard-of-care surgical procedures as an alternative to surgery alone.

Punit Dhillon, OncoSec’s President and CEO, commented, “The issuance of this patent opens the possibility for improving surgical outcomes in cancer therapy. There is a tremendous unmet clinical need, especially for advanced cancer where recurrence rates associated with surgery remain high.Treatment of margin tissue with our therapy potentially expands the market for our product beyond those indications we are currently pursuing for the use of the technology. We envision that surgical margins could be routinely treated with our therapy, providing increased benefit to patients.”

About OncoSec Medical Inc.

OncoSec Medical Incorporated is a biopharmaceuticalcompany developing advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent apotential solution for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from traditional cancer treatments. OncoSec’s core technology is based upon its proprietary use of an electroporation platform, to dramatically enhance the delivery and uptake of a locally delivered DNA-based immuno-cytokine or a chemotherapeutic agent. Treatment of various solid cancers using these targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy targeting lethal skin cancers. More information is available at www.oncosec.com.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause ourresults to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.